Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00863915 · ClinicalTrials.gov registry record · Phase 1

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

A Phase 1 study, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00863915: Completed Phase 1 study, sponsored by Actavis.

NCT00863915 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00863915, a Phase 1 study, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated as a sprinkle on one tablespoonful of applesauce to healthy subjects after a 10-hour overnight fast

Interventions

  • DRUG Ramipril10 mg Capsules, single dose
  • DRUG Atlace® 10 mg capsules, single dose

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2004-10
Est. Completion 2004-10
Phase Phase 1
Actavis

79 total trials

What the finished NCT00863915 record still lists

NCT00863915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which Ramipril10 mg Capsules, single dose is the first listed.

NCT00863915 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00863915 about?

NCT00863915 is a clinical study titled "A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce". To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated as a...

What is the current status of trial NCT00863915?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-10. Estimated completion is 2004-10.

What interventions are being tested in trial NCT00863915?

The interventions under investigation include: Ramipril10 mg Capsules, single dose (DRUG), Atlace® 10 mg capsules, single dose (DRUG).

Who is sponsoring clinical trial NCT00863915?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00863915's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00863915, the US trial registry maintained by the National Library of Medicine. NCT00863915 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.